These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 12559781)
1. HIV-specific immunity during structured antiviral drug treatment interruption. Moss RB; Brandt C; Giermakowska WK; Savary JR; Theofan G; Zanetti M; Carlo DJ; Wallace MR Vaccine; 2003 Mar; 21(11-12):1066-71. PubMed ID: 12559781 [TBL] [Abstract][Full Text] [Related]
2. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Rosenberg ES; Billingsley JM; Caliendo AM; Boswell SL; Sax PE; Kalams SA; Walker BD Science; 1997 Nov; 278(5342):1447-50. PubMed ID: 9367954 [TBL] [Abstract][Full Text] [Related]
3. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Oxenius A; Price DA; Günthard HF; Dawson SJ; Fagard C; Perrin L; Fischer M; Weber R; Plana M; García F; Hirschel B; McLean A; Phillips RE Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13747-52. PubMed ID: 12370434 [TBL] [Abstract][Full Text] [Related]
4. Human immunodeficiency virus-type 1 specific cellular immunity in chronic infected patients on prolonged highly active antiretroviral treatment and on structured treatment interruption. Matsuda R; Boström AC; Fredriksson M; Fredriksson EL; Bratt G; Hejdeman B; Sandström E; Okuda K; Wahren B Microbiol Immunol; 2006; 50(8):629-35. PubMed ID: 16924148 [TBL] [Abstract][Full Text] [Related]
9. Long-term persistence of vaccination and HAART to human immunodeficiency virus (HIV). Boström AC; Hejdeman B; Matsuda R; Fredriksson M; Fredriksson EL; Bratt G; Sandström E; Wahren B Vaccine; 2004 Apr; 22(13-14):1683-91. PubMed ID: 15068851 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic vaccination in primary HIV infection, the Quest trial. Perrin L Vaccine; 2002 May; 20(15):2004-6. PubMed ID: 11983263 [No Abstract] [Full Text] [Related]
11. Lack of longitudinal intrapatient correlation between p24 antigenemia and levels of human immunodeficiency virus (HIV) type 1 RNA in patients with chronic hiv infection during structured treatment interruptions. Prado JG; Shintani A; Bofill M; Clotet B; Ruiz L; Martinez-Picado J J Clin Microbiol; 2004 Apr; 42(4):1620-5. PubMed ID: 15071015 [TBL] [Abstract][Full Text] [Related]
12. Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy. Haslett PA; Nixon DF; Shen Z; Larsson M; Cox WI; Manandhar R; Donahoe SM; Kaplan G J Infect Dis; 2000 Apr; 181(4):1264-72. PubMed ID: 10751137 [TBL] [Abstract][Full Text] [Related]
13. Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. Karlsson AC; Younger SR; Martin JN; Grossman Z; Sinclair E; Hunt PW; Hagos E; Nixon DF; Deeks SG AIDS; 2004 Apr; 18(7):981-9. PubMed ID: 15096800 [TBL] [Abstract][Full Text] [Related]
14. Absence of favourable changes in circulating levels of interleukin-16 or beta-chemokine concentration following structured intermittent interruption treatment of chronic human immunodeficiency virus infection. Montes de Oca Arjona M; Pérez Cano R; Orozco MJ; Martín Aspas A; Guerrero F; Fernández Gutiérrez Del Alamo C; Girón-González JA Clin Microbiol Infect; 2005 Jan; 11(1):57-62. PubMed ID: 15649305 [TBL] [Abstract][Full Text] [Related]
15. HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss. Schüpbach J; Günthard H; Joos B; Fischer M; Böni J; Tomasik Z; Yerly S; Perrin L; Battegay M; Furrer H; Vernazza P; Bernasconi E; Hirschel B; J Acquir Immune Defic Syndr; 2005 Nov; 40(3):250-6. PubMed ID: 16249697 [TBL] [Abstract][Full Text] [Related]
16. Can treatment during primary HIV infection lead to control of disease without drugs? Gegeny T Res Initiat Treat Action; 2002; 7(2):11-4. PubMed ID: 11965922 [TBL] [Abstract][Full Text] [Related]
17. The relationship between T cell proliferative responses and plasma viremia during treatment of human immunodeficiency virus type 1 infection with combination antiretroviral therapy. Binley JM; Schiller DS; Ortiz GM; Hurley A; Nixon DF; Markowitz MM; Moore JP J Infect Dis; 2000 Apr; 181(4):1249-63. PubMed ID: 10762561 [TBL] [Abstract][Full Text] [Related]
18. A therapeutic HIV-1 vaccine enhances anti-HIV-1 immune responses in patients under highly active antiretroviral therapy. Tung FY; Tung JK; Pallikkuth S; Pahwa S; Fischl MA Vaccine; 2016 Apr; 34(19):2225-32. PubMed ID: 27002500 [TBL] [Abstract][Full Text] [Related]
19. HIV-1-Specific CD4 helper function in persons with chronic HIV-1 infection on antiviral drug therapy as measured by ELISPOT after treatment with an inactivated, gp120-depleted HIV-1 in incomplete Freund's adjuvant. Moss RB; Webb E; Giermakowska WK; Jensen FC; Savary JR; Wallace MR; Carlo DJ J Acquir Immune Defic Syndr; 2000 Jul; 24(3):264-9. PubMed ID: 10969351 [TBL] [Abstract][Full Text] [Related]
20. HIV-1-specific T cell precursors with high proliferative capacity correlate with low viremia and high CD4 counts in untreated individuals. Calarota SA; Foli A; Maserati R; Baldanti F; Paolucci S; Young MA; Tsoukas CM; Lisziewicz J; Lori F J Immunol; 2008 May; 180(9):5907-15. PubMed ID: 18424710 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]